Journal
SINGAPORE MEDICAL JOURNAL
Volume 64, Issue 1, Pages 17-26Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/singaporemedj.SMJ-2022-179
Keywords
Antisense oligonucleotides; cell replacement therapy; gene therapy; inherited optic neuropathy; inherited retinal diseases
Categories
Ask authors/readers for more resources
Inherited ocular diseases, such as inherited retinal diseases and inherited optic neuropathies, are a diverse and complex group of rare diseases. Recent advancements in gene therapy, including adeno-associated virus-based gene therapy, have revolutionized the field and opened up new possibilities for treating these diseases. This review explores the mode of inheritance, natural history studies, clinical trial outcomes, and current and emerging therapies, including gene therapy strategies, cell-based therapies, and bionic vision.
Inherited ocular diseases comprise a heterogeneous group of rare and complex diseases, including inherited retinal diseases ( IRDs) and inherited optic neuropathies. Recent success in adeno-associated virus-based gene therapy, voretigene neparvovec (Luxturna (R)) for RPE65-related IRDs, has heralded rapid evolution in gene therapy platform technologies and strategies, from gene augmentation to RNA editing, as well as gene agnostic approaches such as optogenetics. This review discusses the fundamentals underlying the mode of inheritance, natural history studies and clinical trial outcomes, as well as current and emerging therapies covering gene therapy strategies, cell-based therapies and bionic vision.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available